Clinical Trial Update: A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of Herceptin (trastuzumab) in women with HER2-positive advanced or metastatic breast cancer has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-11-22